Efficacy comparison of intravitreal injections of conbercept and ranibizumab for severe proliferative diabetic retinopathy
Efficacy comparison of intravitreal injections of conbercept and ranibizumab for severe proliferative diabetic retinopathy
复制标题
玻璃体内注射康柏西普与雷珠单抗治疗重度增殖性糖尿病视网膜病变的疗效比较
DOI：
10.1016/j.jcjo.2018.06.010
复制
发表时间：
2019-06-01
影响因子：
4.2
通讯作者：
Lu, PeiRong
中科院分区：
文献类型：
--
作者：
Lu, Qianyi;Lu, Li;Lu, PeiRong
Objective: To determine the efficacy of preoperative intravitreal injections of conbercept (IVC) and ranibizumab (IVR) on postoperative best-corrected visual acuity (BCVA), vitreous hemorrhage (VH), and neovascular glaucoma (NVG) in a population with proliferative diabetic retinopathy (PDR) undergoing vitrectomy.Design: Retrospective, cross-sectional study.Participants: 386 patients with severe PDR (428 eyes).Methods: The patients who did not receive IVC or IVR were assigned to group A (125 eyes), the patients who received IVR (0.5 mg) were assigned to group B (146 eyes), and the patients who received IVC (0.5 mg) were assigned to group C (157 eyes).Results: Both group B (p = 0.009) and group C (p = 0.002) had better postoperative BCVA than group A. Early postoperative VH occurred significantly less frequently in group B (22.60%; p = 0.007) and group C (12.10%; p < 0.001) than in group A (37.60%). Importantly, the incidences of postoperative NVG in group B (2.74%; p = 0.001) and group C (0.64%; p < 0.001) were both significantly less than that in group A (15.20%). However, there was no significant difference in the incidences of postoperative NVG between groups B and C (p = 0.325).Conclusions: The contribution of preoperative IVC to an improved BCVA for patients with severe PDR was better than that of IVR, and IVC decreased the risk of postoperative early VH. Pretreatment with IVC or IVR reduced the incidence of postoperative NVG based on the 24-month follow-up data.
